Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(2.24)
# 2,761
Out of 5,130 analysts
40
Total ratings
50%
Success rate
-2.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Maintains: Outperform | $38 → $36 | $17.77 | +102.59% | 1 | Dec 15, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $89 → $94 | $86.57 | +8.58% | 4 | Dec 9, 2025 | |
| VERA Vera Therapeutics | Maintains: Outperform | $75 → $97 | $48.71 | +99.14% | 1 | Dec 8, 2025 | |
| EVMN Evommune | Initiates: Outperform | $40 | $20.13 | +98.71% | 1 | Dec 1, 2025 | |
| FBRX Forte Biosciences | Initiates: Outperform | $65 | $23.88 | +172.19% | 1 | Nov 25, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $775 → $910 | $788.49 | +15.41% | 5 | Oct 31, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $20 → $14 | $1.51 | +827.15% | 4 | Sep 22, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $207 → $222 | $220.08 | +0.87% | 5 | Sep 22, 2025 | |
| PRQR ProQR Therapeutics | Initiates: Outperform | $5 | $1.77 | +182.49% | 1 | Apr 29, 2025 | |
| MNMD Mind Medicine (MindMed) | Initiates: Outperform | $23 | $13.84 | +66.18% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $15 → $6 | $2.10 | +185.71% | 2 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $179 → $170 | $23.83 | +613.39% | 9 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $5.16 | +287.60% | 1 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $201 → $206 | $261.41 | -21.20% | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $2.64 | +733.33% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $10 | $2.14 | +367.29% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $72.86 | -17.65% | 1 | Oct 5, 2022 |
Dyne Therapeutics
Dec 15, 2025
Maintains: Outperform
Price Target: $38 → $36
Current: $17.77
Upside: +102.59%
Mirum Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $89 → $94
Current: $86.57
Upside: +8.58%
Vera Therapeutics
Dec 8, 2025
Maintains: Outperform
Price Target: $75 → $97
Current: $48.71
Upside: +99.14%
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: $40
Current: $20.13
Upside: +98.71%
Forte Biosciences
Nov 25, 2025
Initiates: Outperform
Price Target: $65
Current: $23.88
Upside: +172.19%
argenx SE
Oct 31, 2025
Maintains: Outperform
Price Target: $775 → $910
Current: $788.49
Upside: +15.41%
Jasper Therapeutics
Sep 22, 2025
Maintains: Outperform
Price Target: $20 → $14
Current: $1.51
Upside: +827.15%
AbbVie
Sep 22, 2025
Maintains: Outperform
Price Target: $207 → $222
Current: $220.08
Upside: +0.87%
ProQR Therapeutics
Apr 29, 2025
Initiates: Outperform
Price Target: $5
Current: $1.77
Upside: +182.49%
Mind Medicine (MindMed)
Jan 28, 2025
Initiates: Outperform
Price Target: $23
Current: $13.84
Upside: +66.18%
Dec 20, 2024
Downgrades: In-Line
Price Target: $15 → $6
Current: $2.10
Upside: +185.71%
Nov 7, 2024
Maintains: Outperform
Price Target: $179 → $170
Current: $23.83
Upside: +613.39%
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $5.16
Upside: +287.60%
Aug 12, 2024
Maintains: Outperform
Price Target: $201 → $206
Current: $261.41
Upside: -21.20%
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $2.64
Upside: +733.33%
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $2.14
Upside: +367.29%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $72.86
Upside: -17.65%